Small Molecule Modulators of Keap1‐Nrf2‐ARE Pathway as Potential Preventive and Therapeutic Agents

Medicinal Research Reviews - Tập 32 Số 4 - Trang 687-726 - 2012
Sadagopan Magesh1, Yu Chen1, Longqin Hu1,2
1Department of Medicinal Chemistry Ernest Mario School of Pharmacy Rutgers, The State University of New Jersey 160 Frelinghuysen Road Piscataway New Jersey 08854
2The Cancer Institute of New Jersey New Brunswick New Jersey 08854

Tóm tắt

AbstractKelch‐like ECH‐associated protein 1 (Keap1)‐nuclear factor erythroid 2‐related factor 2 (Nrf2)‐antioxidant response elements (ARE) pathway represents one of the most important cellular defense mechanisms against oxidative stress and xenobiotic damage. Activation of Nrf2 signaling induces the transcriptional regulation of ARE‐dependent expression of various detoxifying and antioxidant defense enzymes and proteins. Keap1‐Nrf2‐ARE signaling has become an attractive target for the prevention and treatment of oxidative stress‐related diseases and conditions including cancer, neurodegenerative, cardiovascular, metabolic, and inflammatory diseases. Over the last few decades, numerous Nrf2 inducers have been developed and some of them are currently undergoing clinical trials. Recently, overactivation of Nrf2 has been implicated in cancer progression as well as in drug resistance to cancer chemotherapy. Thus, Nrf2 inhibitors could potentially be used to improve the effectiveness of cancer therapy. Herein, we review the signaling mechanism of Keap1‐Nrf2‐ARE pathway, its disease relevance, and currently known classes of small molecule modulators. We also discuss several aspects of Keap1–Nrf2 interaction, Nrf2‐based peptide inhibitor design, and the screening assays currently used for the discovery of direct inhibitors of Keap1‐Nrf2 interaction. © 2012 Wiley Periodicals, Inc. Med Res Rev., 32, No. 4, 687‐726, 2012

Từ khóa


Tài liệu tham khảo

10.1038/35041687

10.2174/0929867013372896

10.1002/jps.20874

Devasagayam TP, 2004, Free radicals and antioxidants in human health: Current status and future prospects, J Assoc Physicians India, 52, 794

10.2174/092986710792231950

10.1038/nrd1330

10.1038/nrc2522

10.2174/187221309787158371

10.1002/ijc.23192

10.1021/tx700210j

Sen S, 2010, Free radicals, antioxidants, diseases and phytomedicines: Current status and future prospect, Int J Pharm Sci Rev Res, 3, 91

10.1016/0271-5317(95)00041-G

10.1134/S0006297906090033

10.1016/S0300-483X(03)00151-3

Dinkova‐Kostova AT, 2008, Direct and indirect antioxidant properties of inducers of cytoprotective proteins, Mol Nutr Food Res, 52, S128

10.1002/biof.5520120102

10.1016/j.advenzreg.2003.11.013

10.1006/bbrc.1997.6943

10.1101/gad.13.1.76

10.1016/j.freeradbiomed.2004.04.033

10.1007/s00204-011-0694-1

10.1007/s00204-011-0674-5

10.1016/j.stem.2010.12.006

10.1055/s-0028-1088302

10.1089/ars.2010.3534

10.1016/j.tibs.2008.12.008

10.1146/annurev.pharmtox.46.120604.141046

10.5483/BMBRep.2004.37.2.139

10.1111/j.1365-2443.2010.01473.x

10.1089/ars.2008.2242

10.1089/ars.2006.8.99

10.1002/bies.20359

10.1016/j.phrs.2008.09.003

10.1358/dnp.2007.20.2.1083437

10.1517/14728220903025762

10.1016/j.mrfmmm.2005.04.017

10.3390/molecules15107266

10.1159/000327599

10.1056/NEJMoa1105351

10.1158/1078-0432.CCR-09-3272

10.1111/j.2042-7158.2011.01259.x

10.1158/1940-6207.CAPR-10-0296

10.1207/s15327914nc5501_7

10.1016/j.cbpa.2010.12.009

10.1097/MCO.0b013e32834136f2

10.1038/onc.2010.492

10.1007/s00204-011-0675-4

10.1093/carcin/bgp231

10.1134/S0006297911040031

10.1016/j.niox.2011.02.007

10.1016/j.taap.2010.01.011

10.1074/jbc.M109380200

10.1089/ars.2010.3211

10.1128/MCB.26.1.221-229.2006

10.1089/ars.2005.7.385

Eggler AL, 2008, Molecular mechanisms of natural products in chemoprevention: Induction of cytoprotective enzymes by Nrf2, Mol Nutr Food Res, 52, S84

10.1042/bss0710157

10.1080/03602530600971974

10.1007/s11095-010-0096-8

10.2174/1381612043452901

10.1016/j.taap.2009.06.009

10.1016/j.freeradbiomed.2009.07.035

10.1073/pnas.0307301101

10.1073/pnas.0308347100

10.1128/MCB.24.16.7130-7139.2004

10.1074/jbc.M206530200

10.1073/pnas.172398899

10.1016/j.jasms.2007.09.015

10.1074/jbc.M403061200

10.1042/BJ20060725

10.1128/MCB.25.24.10895-10906.2005

10.1074/jbc.M502083200

10.1046/j.1365-2443.2002.00561.x

10.1128/MCB.25.18.8044-8051.2005

10.1002/mc.20465

10.1128/MCB.23.22.8137-8151.2003

10.1021/tx700302s

10.1042/BJ20030754

10.1093/carcin/bgp176

10.1073/pnas.94.10.5361

10.1126/scisignal.3112re3

10.1074/jbc.M500166200

10.1016/S0021-9258(18)99004-6

10.1089/ars.2010.3301

10.1074/jbc.M501279200

10.1074/jbc.M503346200

10.1074/jbc.M601119200

10.1016/j.taap.2009.08.018

10.1515/BC.2006.164

10.1128/MCB.00753-07

10.1128/MCB.26.8.2887-2900.2006

10.1042/BJ20090471

10.1128/MCB.00630-07

10.1074/jbc.M110.121863

10.1089/ars.2009.2609

10.1016/j.freeradbiomed.2011.01.033

10.1089/ars.2010.3216

10.1126/scisignal.2000762

10.1089/ars.2010.3400

10.1128/MCB.01080-08

10.1128/MCB.01704-07

10.1124/mol.109.058453

10.1096/fj.04-2591hyp

10.1093/icb/icq034

10.1016/j.taap.2009.08.028

10.1093/carcin/bgm049

10.1007/s00018-008-7452-4

10.1158/1535-7163.MCT-08-0625

10.1093/carcin/bgn095

10.1093/cvr/cvp031

10.1016/j.molcel.2006.03.004

10.1073/pnas.0806268105

10.1158/0008-5472.CAN-07-5003

10.1073/pnas.1014275108

10.1016/j.freeradbiomed.2011.03.008

10.1165/rcmb.2007-0424OC

10.1096/fj.06-7759com

10.1016/j.molmed.2011.02.006

10.1016/j.taap.2009.07.024

10.2174/156652408785160925

10.1016/j.freeradbiomed.2008.09.001

10.1089/ars.2010.3731

10.1016/j.freeradbiomed.2008.11.003

Tufekci KU, 2011, The Nrf2/ARE pathway: A promising target to counteract mitochondrial dysfunction in Parkinson's disease, Parkinsons Dis, 2011, 314082

10.1074/jbc.M210105200

10.1097/nen.0b013e31802d6da9

10.1073/pnas.0813361106

10.1007/s11064-008-9775-9

10.2174/1568007054038238

10.1111/j.1749-6632.2010.05559.x

10.1371/journal.pone.0008391

10.1161/CIRCRESAHA.108.188771

10.1371/journal.pone.0003791

10.1002/eji.201041316

10.1089/ars.2010.3283

10.1016/j.yjmcc.2008.10.007

WangX HaiCX.ROSacts as a double‐edged sword in the pathogenesis of type 2 diabetes mellitus: IsNrf2 a potential target for the treatment?Mini Rev Med Chem2011.

10.2337/db09-1342

10.1016/j.bbrc.2011.03.087

10.1053/j.gastro.2009.03.033

10.1158/0008-5472.CAN-06-3562

10.1080/01926230701311344

10.1016/j.freeradbiomed.2009.04.033

10.1136/ard.2010.132720

10.1089/ars.2010.3835

10.1016/j.taap.2008.03.003

Dimmock JR, 1999, Bioactivities of chalcones, Curr Med Chem, 6, 1125, 10.2174/0929867306666220401182509

10.1016/j.toxlet.2011.04.011

10.1073/pnas.1007387107

10.1074/jbc.M109.051714

10.1007/978-3-642-00663-0_9

10.1073/pnas.0502402102

10.1074/jbc.M110.163485

10.1016/S0076-6879(04)82014-7

10.1016/S0076-6879(04)82023-8

10.1073/pnas.051632198

10.1271/bbb.90731

10.1080/10408440801981957

10.1016/j.cbi.2008.05.003

10.1093/carcin/20.5.911

10.1089/ars.2006.8.395

10.1042/BJ20021619

McNally SJ, 2007, Curcumin induces heme oxygenase 1 through generation of reactive oxygen species, p38 activation and phosphatase inhibition, Int J Mol Med, 19, 165

10.1208/aapsj080352

10.1093/carcin/bgn064

10.1016/j.bcp.2007.08.016

10.1016/j.canlet.2006.01.024

Michaluart P, 1999, Inhibitory effects of caffeic acid phenethyl ester on the activity and expression of cyclooxygenase‐2 in human oral epithelial cells and in a rat model of inflammation, Cancer Res, 59, 2347

10.1021/jf011348w

10.1089/ars.2004.6.811

10.2174/0929867053363153

10.1016/j.bbrc.2010.06.124

10.1016/j.tiv.2009.12.024

10.1021/jm2002348

10.1016/j.chembiol.2011.03.013

10.1016/j.toxlet.2008.12.014

Pokharel YR, 2006, Screening of potential chemopreventive compounds from Poncirus trifoliata Raf, Pharmazie, 61, 796

Song LL, 1999, Cancer chemopreventive activity mediated by 4’‐bromoflavone, a potent inducer of phase II detoxification enzymes, Cancer Res, 59, 578

10.1016/j.bmc.2008.12.052

10.1016/j.febslet.2004.07.042

10.1089/jmf.2009.0072

10.1089/ars.2008.2292

10.1021/jf101353c

Nishino H, 1988, Inhibition of the tumor‐promoting action of 12‐O‐tetradecanoylphorbol‐13‐acetate by some oleanane‐type triterpenoid compounds, Cancer Res, 48, 5210

10.1073/pnas.0500815102

10.1021/np100826q

10.1158/1535-7163.MCT-07-0180

10.1016/j.bmcl.2011.03.018

10.1021/jm101445p

10.1172/JCI200418699

10.1016/j.freeradbiomed.2009.06.030

10.1074/jbc.M110.190710

10.1111/j.1365-2443.2010.01466.x

10.1016/j.ejphar.2010.06.040

10.1016/j.chembiol.2010.03.013

10.1002/biof.5520130123

Benson AM, 1979, Elevation of extrahepatic glutathione S‐transferase and epoxide hydratase activities by 2(3)‐tert‐butyl‐4‐hydroxyanisole, Cancer Res, 39, 2971

10.1073/pnas.77.9.5216

10.1016/0006-2952(85)90443-5

10.1016/j.cbi.2010.09.010

10.1073/pnas.82.23.8232

10.1016/j.chembiol.2009.12.013

10.1002/jnr.20974

ShawP MeadR HigginbottomA BarberS;Therapeutics for neurological disorders. UK Patent Application. 2010 Priority Date 24.10.2008. Publ Date 05.05.2010.

10.1016/j.canlet.2008.03.046

10.1016/j.freeradbiomed.2007.02.017

10.1002/jcb.23158

10.1016/j.bbrc.2006.05.197

10.1016/j.coph.2008.12.012

10.1016/j.cub.2005.12.038

10.1152/ajplung.00361.2007

10.1152/ajpheart.00260.2010

10.1080/10408390802145310

10.1016/j.pupt.2008.12.010

10.1007/s11095-005-7546-8

10.1074/jbc.M309660200

10.1111/j.1471-4159.2007.05039.x

10.1016/j.neulet.2008.09.079

10.1021/tx100427p

10.1016/S0031-9422(00)00316-2

10.1146/annurev.arplant.57.032905.105228

10.1208/s12248-009-9162-8

10.1021/tx100389r

10.1073/pnas.1004104107

10.1021/tx0502138

10.1007/s11095-007-9370-9

10.1021/jm00027a021

10.1007/s11010-007-9598-z

10.1093/carcin/15.2.177

10.1074/jbc.M211898200

10.1021/tx980185b

10.1016/j.cbi.2008.12.001

10.1002/biof.5520260201

10.1124/dmd.106.014340

10.1016/S0278-6915(00)00171-X

10.1023/B:MCBI.0000007260.32981.b9

10.1016/j.taap.2005.01.048

Elangovan S, 2008, Control of cellular redox status and upregulation of quinone reductase NQO1 via Nrf2 activation by alpha‐lipoic acid in human leukemia HL‐60 cells, Int J Oncol, 33, 833

10.1016/j.bbagen.2009.07.026

10.1016/j.tox.2005.12.016

10.1016/j.bmcl.2010.01.044

10.1016/0306-3623(95)00003-J

10.1021/tx0601105

10.1016/j.bmc.2010.08.019

10.1016/j.phrs.2007.01.012

10.1016/j.freeradbiomed.2009.06.008

10.2174/0929867053764635

10.1016/j.taap.2009.01.011

10.1021/tx800019a

10.1254/jphs.09330FP

10.1093/carcin/bgp182

10.1016/j.exphem.2004.01.007

10.1074/jbc.M604748200

10.1073/pnas.0709483104

10.1016/j.tet.2006.01.083

10.1021/jf904061x

10.1093/toxsci/kfl169

10.1111/j.1439-0396.2008.00838.x

10.2174/156802607780906825

10.1038/nature01985

10.1038/sj.emboj.7601243

10.1074/jbc.M410073200

10.1107/S0907444905022626

10.1038/sj.emboj.7601243

10.1016/j.molcel.2006.01.013

10.1111/j.1747-0285.2011.01240.x

10.1161/STROKEAHA.107.486506

10.1016/j.brainres.2010.04.036

10.1016/j.brainres.2009.05.009

10.1523/JNEUROSCI.1683-07.2007

10.1016/j.bbrc.2011.03.046

10.1006/abbi.1998.1046

10.1016/j.jala.2008.03.007

10.1016/j.mrgentox.2009.12.007

10.1128/MCB.24.24.10941-10953.2004

10.1016/j.chembiol.2011.03.013

10.1177/1087057111430124